Gene Therapy News

  • Aug 10, 2016 Five-year, $11 million grant to fund new approaches to gene therapy

    Five-year, $11 million grant to fund new approaches to gene therapy

    An innovative program project grant that will fund new approaches to gene therapy for alpha-1 antitrypsin deficiency has been awarded to a multidisciplinary team of researchers and clinicians at UMass Medical School by the National Heart, Lung and Blood Institute. The grant, totaling more than $11 million over five years, will be used to investigate three different genetically based approaches to treat the disease.

  • Jun 2, 2016 GSBS class speaker Aditya Venkatesh focused on translating research to therapeutics

    GSBS class speaker Aditya Venkatesh focused on translating research to therapeutics

    Graduate School of Biomedical Sciences Class of 2016 speaker Aditya Venkatesh will reflect on his path to science when he takes the stage at the 43rdUMass Medical School Commencement on Sunday, June 5. As a child growing up in India, he said he was fascinated by biology and dreamed of becoming a doctor.

  • May 24, 2016 Washington Post: Ancient sheep help in quest for Tay-Sachs treatment

    Washington Post: Ancient sheep help in quest for Tay-Sachs treatment

    Miguel Sena-Esteves, PhD, associate professor of neurology and a member of the Horae Gene Therapy Center, talked to the Washington Post about the progress he and others have made in developing a gene therapy treatment for the disease.

  • May 3, 2016 UMMS gene therapy experts to present new discoveries at inKNOWvation panel discussion

    UMMS gene therapy experts to present new discoveries at inKNOWvation panel discussion

    Scientists at UMass Medical School will share their latest research at an inKNOWvation panel discussion, “The Return of Gene Therapy,” on Wednesday, May 11, at the Massachusetts Biotechnology Council in Cambridge.

  • Apr 29, 2016 Newsweek: UMass Medical School develops gene therapy for rare neurodegenerative disease

    Newsweek: UMass Medical School develops gene therapy for rare neurodegenerative disease

    Researchers in the lab of Guangping Gao, PhD, have developed a novel gene therapy that cures the rare, inherited neurodegenerative disorder Canavan disease in mice and is on track to be brought to clinical trial

  • Aug 17, 2015 Horae Oriental endows Gene Therapy Center at UMass Medical School with $2M gift

    Horae Oriental endows Gene Therapy Center at UMass Medical School with $2M gift

    The Gene Therapy Center, a global leader in adeno-associated virus (AAV) gene therapy, has received a $2 million endowment from the Horae Oriental Shenzhen Investment Company of Guangdong, China. In recognition of the gift, the Gene Therapy Center has been named the Horae (红瑞) Gene Therapy Center.

  • Mar 15, 2015 Terence R. Flotte appointed editor-in-chief of journal Human Gene Therapy

    Terence R. Flotte appointed editor-in-chief of journal Human Gene Therapy

    Terence R. Flotte, MD, the Celia and Isaac Haidak Professor of Medical Education, executive deputy chancellor, provost and dean of the School of Medicine, is the new editor-in-chief of the journal Human Gene Therapy and its associated periodicalsHuman Gene Therapy Methods and Human Gene Therapy Clinical Development, effective July 1. Dr. Flotte is currently an associate editor of the journal.

  • Feb 17, 2015 LYSOGENE, University of Massachusetts Medical School and Auburn University Announce Collaboration Agreement

    LYSOGENE, University of Massachusetts Medical School and Auburn University Announce Collaboration Agreement

    LYSOGENE today announced that it has entered into a strategic collaboration with the University of Massachusetts Medical School (UMMS) in Worcester, Massachusetts, and Auburn University (AU) in Auburn, Alabama. Through the collaboration, LYSOGENE, UMMS and AU will develop IND-supporting preclinical studies in GM1-gangliosidosis, a rare, inherited disorder characterized by severe neurological impairment, using adeno-associated virus (AAV) gene therapy technology.

  • Oct 22, 2014 UMMS celebrates opening of Voyager Therapeutics headquarters

    UMMS celebrates opening of Voyager Therapeutics headquarters

    UMass Medical School celebrated the opening of Voyager Therapeutics’ new headquarters in Cambridge yesterday. Voyager is a gene therapy company founded by four world leaders in the fields of AAV (adeno-associated virus) gene therapy, RNA biology and neuroscience to develop life-changing treatments for fatal and debilitating diseases of the central nervous system.

  • Feb 19, 2014 Voyager Therapeutics targets novel gene therapies to combat diseases

    Voyager Therapeutics targets novel gene therapies to combat diseases

    UMass Medical School recognizes the launch today of Voyager Therapeutics, a gene therapy company founded by four world leaders in the fields of AAV gene therapy, RNA biology and neuroscience, to develop life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS).

Showing 1-10 of 13 items
of 2

▴ Back To Top
Section Menu To Top